Adverum Biotechnologies
ADVM
ADVM was delisted on the 8th of December, 2025.
69 hedge funds and large institutions have $74.1M invested in Adverum Biotechnologies in 2024 Q4 according to their latest regulatory filings, with 9 funds opening new positions, 27 increasing their positions, 12 reducing their positions, and 17 closing their positions.
125% more repeat investments, than reductions
Existing positions increased: 27 | Existing positions reduced: 12
100% more funds holding in top 10
Funds holding in top 10: 2 → 4 (+2)
5.13% less ownership
Funds ownership: 81.45% → 76.32% (-5.1%)
10% less funds holding
Funds holding: 77 → 69 (-8)
27% less call options, than puts
Call options by funds: $45K | Put options by funds: $62K
38% less capital invested
Capital invested by funds: $120M → $74.1M (-$46M)
47% less first-time investments, than exits
New positions opened: 9 | Existing positions closed: 17
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Citadel Advisors
Miami,
Florida
|
+$845K |
| 2 |
Dimensional Fund Advisors
Austin,
Texas
|
+$702K |
| 3 |
Renaissance Technologies
New York
|
+$623K |
| 4 |
Goldman Sachs
New York
|
+$516K |
| 5 |
TI
Trexquant Investment
Stamford,
Connecticut
|
+$405K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
VA
VR Adviser
New York
|
-$10.3M |
| 2 |
VC
Vivo Capital
Palo Alto,
California
|
-$5.85M |
| 3 |
LGM
Logos Global Management
San Francisco,
California
|
-$2.92M |
| 4 |
TCM
TCG Crossover Management
Palo Alto,
California
|
-$1.43M |
| 5 |
Fidelity Investments
Boston,
Massachusetts
|
-$1.19M |
ADVM Hedge Fund Activity: Q4 2024 in Review
69 of the 7,593 institutional investors tracked by Wall St. Rank reported a position in Adverum Biotechnologies (ADVM) for Q4 2024, worth a combined $74.1M — down 38% from $120M a quarter earlier.
Sellers outnumbered buyers: 17 funds closed out of ADVM and 9 opened new positions — a net loss of 8 holders — while 12 trimmed existing stakes and 27 added.
The largest buyer was Citadel Advisors, adding an estimated $845K. The largest seller was VR Adviser, exiting entirely with an estimated $10.3M sold.
- 69 institutional investors held Adverum Biotechnologies (ADVM) as of Q4 2024, down from 77 in Q3 2024.
- Funds reported $74.1M of Adverum Biotechnologies stock for Q4 2024, down 38% quarter-over-quarter.
- 9 funds opened new Adverum Biotechnologies positions in Q4 2024 and 17 closed out, a net change of -8 holders.
- The largest Adverum Biotechnologies buyer in Q4 2024 was Citadel Advisors, an estimated $845K added.
- The largest Adverum Biotechnologies seller in Q4 2024 was VR Adviser, an estimated $10.3M sold.
Based on aggregated 13F filings for Q4 2024.